PolyMedix Inc. (PYMX) Provides Updates on Its Two Lead Clinical Programs
PolyMedix Inc. is a biotechnology company focused on the development of novel drugs for the treatment of serious infectious diseases and acute cardiovascular disorders. The company today provided an update for its two lead clinical programs. These programs are the heptagonist PMX-60056 and the defensin-mimetic antibiotic PMX-30063. PolyMedix anticipates conducting a Phase 1B/2 dose-ranging clinical trial for heptagonist PMX-60056 in the upcoming months. The trial is designed to evaluate the reversal of the low molecular weight heparin exoxoparin in healthy subjects. Data from this clinical trial will be used to establish a dose response correlation for enoxoparin and guide dosing…